Muscle protection following motor nerve repair in combination with leukemia inhibitory factor.
Leukemia inhibitory factor (LIF) has been shown to stimulate growth of muscle and nerve cells. In this rat study, in which the nerve to the medial head of the gastrocnemius was divided and repaired and slow-release LIF was administered at the repair site, we evaluated recovery by measuring the force of muscle contraction and of muscle bulk. Thirty-five male Sprague-Dawley rats (325-375 g) were randomly divided into 5 different groups according to type of treatment: denervated, end-to-end nerve repair, end-to-end nerve repair with LIF, neurotization, and neurotization with LIF. The contralateral side served as a nonoperated control group. Leukemia inhibitory factor was administered for 28 days to the site of the nerve repair via an implanted osmotic infusion pump. Muscle mass and muscular function were evaluated at 6 weeks using electrophysiologic techniques. The medial gastrocnemius muscle mass of the repair + LIF group was greater than the repair-alone group. The peak twitch, relative twitch, relative tetanic, and tetanic forces generated from the repair + LIF group were also significantly higher than those in the repair-alone group. Although neurotization was almost as effective as end-to-end nerve repair for reinnervating muscle, LIF had no increased effect on neurotization. These data suggest that LIF protects muscular function and reduces denervation atrophy following end-to-end nerve repair.
Bernard O'Brien Institute of Microsurgery, St Vincent's Hospital, Department of Neurosciences, The University of Melbourne, Fitzroy, Victoria, Australia.
J
J
Leong
A
A
Hayes
L
L
Austin
W
W
Morrison
D000818:Animals; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D006614:Hindlimb; D066298:In Vitro Techniques; D007260:Infusion Pumps; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009119:Muscle Contraction; D018482:Muscle, Skeletal / Q000294:innervation* / Q000473:pathology / Q000503:physiopathology; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000494:pharmacology*; D009416:Nerve Regeneration; D016067:Nerve Transfer; D009995:Osmosis; D010525:Peripheral Nerves / Q000502:physiology / Q000601:surgery*; D051381:Rats; D017207:Rats, Sprague-Dawley
D006131:Growth Inhibitors; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D009414:Nerve Growth Factors